

The United States of America



The Director of the United States Patent and Trademark Office

J11650 U.S. PTO
10/304072
11/26/02

Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this

United States Patent

Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America for the term set forth below, subject to the payment of maintenance fees as provided by law.

If this application was filed prior to June 8, 1995, the term of this patent is the longer of seventeen years from the date of grant of this patent or twenty years from the earliest effective U.S. filing date of the application, subject to any statutory extension.

If this application was filed on or after June 8, 1995, the term of this patent is twenty years from the U.S. filing date, subject to any statutory extension. If the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121 or 365(c), the term of the patent is twenty years from the date on which the earliest application was filed, subject to any statutory extensions.

Director of the United States Patent and Trademark Office



US006153632A

United States Patent [19]**Rieveley**[11] **Patent Number:** **6,153,632**[45] **Date of Patent:** **Nov. 28, 2000**[54] **METHOD AND COMPOSITION FOR THE TREATMENT OF DIABETES**5,422,125 6/1995 Skyler et al. 426/646
5,595,763 1/1997 Guinovart et al. 424/617[76] **Inventor:** **Robert B. Rieveley**, 4102 Yuculta
Crescent, Vancouver, British Columbia,
Canada, V6N 3R5[21] **Appl. No.:** **08/804,903**[22] **Filed:** **Feb. 24, 1997**[51] **Int. Cl.⁷** **A61K 31/425**; **A61K 38/28**;
A61K 31/175; **A61K 31/155**[52] **U.S. Cl.** **514/369**; **514/3**; **514/592**;
514/635; **514/866**[58] **Field of Search** **514/3**, **369**, **592**,
514/866, **635**[56] **References Cited****U.S. PATENT DOCUMENTS**4,708,868 11/1987 Brickl et al. 514/309
4,849,405 7/1989 Ecanow 514/3
4,873,080 10/1989 Brickl et al. 514/315
4,963,526 10/1990 Ecanow 514/3
5,206,219 4/1993 Desai 514/3**OTHER PUBLICATIONS**Weinstock et al., Pioglitazone. In vitro effects on rat
hepatoma cells and in vivo liver hypertrophy in KKAY mice,
(1997) abstract.
Windoliz et al., The Merck Index, Tenth Ed. (1983) pp. 723
and 724, abstract No. 4866.*Primary Examiner*—Kevin E. Weddington*Attorney, Agent, or Firm*—Oyen Wiggs Green & Mutala[57] **ABSTRACT**

This invention is directed to a novel method and composition for the treatment of diabetes mellitus (Type I, Impaired Glucose Tolerance ["IGT"] and Type II). More specifically, this invention pertains to a novel method of treating diabetes mellitus by incorporating a therapeutic amount of one or more insulin sensitizers along with one or more of an orally ingested insulin, an injected insulin, a sulfonylurea, a biguanide or an alpha-glucosidase inhibitor for the treatment of diabetes mellitus.

24 Claims, No Drawings